ATE459652T1 - Verfahren zur herstellung von antikörpern - Google Patents

Verfahren zur herstellung von antikörpern

Info

Publication number
ATE459652T1
ATE459652T1 AT04734554T AT04734554T ATE459652T1 AT E459652 T1 ATE459652 T1 AT E459652T1 AT 04734554 T AT04734554 T AT 04734554T AT 04734554 T AT04734554 T AT 04734554T AT E459652 T1 ATE459652 T1 AT E459652T1
Authority
AT
Austria
Prior art keywords
cells
antibody
producing antibodies
culturing
captured
Prior art date
Application number
AT04734554T
Other languages
English (en)
Inventor
Alastair David Griffiths Lawson
Daniel John Lightwood
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of ATE459652T1 publication Critical patent/ATE459652T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT04734554T 2003-05-30 2004-05-24 Verfahren zur herstellung von antikörpern ATE459652T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0312481.5A GB0312481D0 (en) 2003-05-30 2003-05-30 Antibodies
PCT/GB2004/002226 WO2004106377A1 (en) 2003-05-30 2004-05-24 Methods for producing antibodies

Publications (1)

Publication Number Publication Date
ATE459652T1 true ATE459652T1 (de) 2010-03-15

Family

ID=9959074

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04734554T ATE459652T1 (de) 2003-05-30 2004-05-24 Verfahren zur herstellung von antikörpern

Country Status (10)

Country Link
US (1) US7790414B2 (de)
EP (1) EP1633787B1 (de)
JP (1) JP4624357B2 (de)
AT (1) ATE459652T1 (de)
AU (1) AU2004242823A1 (de)
CA (1) CA2526546A1 (de)
DE (1) DE602004025805D1 (de)
ES (1) ES2341544T3 (de)
GB (1) GB0312481D0 (de)
WO (1) WO2004106377A1 (de)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
US7566772B2 (en) * 2005-01-26 2009-07-28 Amgen Fremont Inc. Antibodies against interleukin-1β
GB0506912D0 (en) 2005-04-05 2005-05-11 Celltech R&D Ltd Biological products
CA2620362A1 (en) 2005-09-14 2007-03-22 Ucb Pharma S.A. Comb polymers
MY147217A (en) 2005-12-09 2012-11-14 Ucb Pharma Sa Antibody molecules having specificity for human il-06
EP3366702B1 (de) 2005-12-13 2023-08-09 Eli Lilly And Company Anti-il-17-antikörper
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
WO2008045140A1 (en) 2006-05-19 2008-04-17 Alder Biopharmaceuticals, Inc. Culture method for obtaining a clonal population of antigen-specific b cells
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
GB0613209D0 (en) 2006-07-03 2006-08-09 Ucb Sa Methods
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
AU2007284782B2 (en) * 2006-08-11 2012-11-15 Merck Sharp & Dohme Corp. Antibodies to IL-17A
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2012130874A1 (en) 2011-03-28 2012-10-04 Ablynx Nv Bispecific anti-cxcr7 immunoglobulin single variable domains
US9156914B2 (en) 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
US20100062004A1 (en) 2006-12-19 2010-03-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US9056905B2 (en) 2007-05-21 2015-06-16 Alderbio Holdings Llc Antibodies to TNF-α and use thereof
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US7935340B2 (en) 2007-05-21 2011-05-03 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
ES2667729T3 (es) 2007-09-26 2018-05-14 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
KR20100097716A (ko) 2007-11-27 2010-09-03 아블린쓰 엔.브이. 이종이량체 사이토킨 및/또는 이의 수용체에 대한 아미노산 서열과 이를 포함하는 폴리펩티드
EP2221384A4 (de) * 2007-12-03 2011-04-06 Advance Kk Verfahren zur herstellung eines antikörpers
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
EP2098536A1 (de) 2008-03-05 2009-09-09 4-Antibody AG Isolation und Identifikation antigen- oder ligandenspezifischer Bindungsproteine
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
RU2010151725A (ru) 2008-05-16 2012-06-27 Аблинкс Нв (Be) Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их
CN102112155B (zh) 2008-06-05 2016-08-10 埃博灵克斯股份有限公司 针对病毒包膜蛋白的氨基酸序列和用于治疗病毒疾病的包含其的多肽
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
EP2370465B1 (de) 2008-12-19 2019-01-23 Ablynx N.V. Genetische immunisierung zur herstellung von immunoglobulinen gegen zell-assoziierte antigene wie p2x7, cxcr7 oder cxcr4
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
MY157473A (en) 2009-02-17 2016-06-15 Ucb Biopharma Sprl Antibody molecules having specificity for human ox40
GB0903207D0 (en) 2009-02-25 2009-04-08 Ucb Pharma Sa Method for expressing multimeric proteins
TR201818431T4 (tr) 2009-02-25 2019-01-21 Ucb Biopharma Sprl Antikorlar Üretmek İçin Usul
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
WO2010129541A1 (en) * 2009-05-04 2010-11-11 Affomix Corporation Emulsion selection of antibodies
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
US8734798B2 (en) 2009-10-27 2014-05-27 Ucb Pharma S.A. Function modifying NAv 1.7 antibodies
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
WO2011066378A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat thrombosis
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2011067160A1 (en) 2009-12-01 2011-06-09 Ablynx Nv Von willebrand factor specific binding agents and uses thereof
FI3309176T3 (fi) 2009-12-14 2026-01-09 Ablynx Nv Immunoglobuliinin yksittäinen vaihteleva domeeni -vasta-aineita ox40l:ää vastaan, konstrukteja ja niiden terapeuttinen käyttö
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2545078A1 (de) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1-antikörper
US10472426B2 (en) 2010-03-25 2019-11-12 Ucb Biopharma Sprl Disulfide stabilized DVD-Ig molecules
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
NZ603570A (en) 2010-05-20 2014-12-24 Ablynx Nv Biological materials related to her3
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
KR101832040B1 (ko) 2010-11-08 2018-04-04 노파르티스 아게 Ｃｘｃｒ２ 결합 폴리펩티드
AU2011332810A1 (en) 2010-11-23 2013-06-13 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of oral mucositis
SG10201510762YA (en) 2011-01-14 2016-01-28 Ucb Pharma Sa Antibody molecules which bind il-17a and il-17f
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP4350345A3 (de) 2011-06-23 2024-07-24 Ablynx N.V. Verfahren zur vorhersage, erkennung und reduzierung von aspezifischer proteininterferenz in tests mit variablen immunglobulin-einzeldomänen
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2944654A1 (de) 2011-06-23 2015-11-18 Ablynx N.V. Verfahren für vorhersage, nachweis und verringerung von aspezifischer proteininterferenz bei tests mit variablen immunglobulin-einzeldomänen
EP2753697A1 (de) 2011-09-05 2014-07-16 ETH Zürich Biosynthetischer gencluster zur herstellung von peptid- bzw. protein-analoga
LT2758432T (lt) 2011-09-16 2019-06-10 Ucb Biopharma Sprl Neutralizuojantys antikūnai prieš clostridium difficile tcda ir tcdb ekzotoksinus
LT2776466T (lt) 2011-11-11 2017-11-27 Ucb Biopharma Sprl Albuminą prisijungiantys antikūnai ir jų prisijungimo fragmentai
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
FR2987627B1 (fr) 2012-03-05 2016-03-18 Splicos Utilisation de rbm39 comme biomarqueur
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
US10048253B2 (en) 2012-06-28 2018-08-14 Ucb Biopharma Sprl Method for identifying compounds of therapeutic interest
EP2727942A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispezifische Antikörper gegen menschliche EGFR, HER2 und HER3
EP2727943A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispezifische Antikörper gegen menschliche EGFR, HER2 und HER3
US20150259430A1 (en) 2012-11-05 2015-09-17 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727941A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Verfahren zur Herstellung multispezifischer Antikörper
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
TR201802728T4 (tr) 2013-10-25 2018-03-21 Psioxus Therapeutics Ltd Heterolog genlerle donatılmış onkolitik adenovirüsler.
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
CN107428827A (zh) 2015-03-18 2017-12-01 宜康公司 通过b细胞淘选和增殖高通量产生单克隆抗体
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
AU2016254215A1 (en) 2015-04-30 2017-10-26 President And Fellows Of Harvard College Anti-aP2 antibodies and antigen binding agents to treat metabolic disorders
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
WO2016189045A1 (en) 2015-05-27 2016-12-01 Ucb Biopharma Sprl Method for the treatment of neurological disease
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CA2990305A1 (en) 2015-06-26 2016-12-29 Mab Discovery Gmbh Monoclonal anti-il-1racp antibodies
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
EP3356398B1 (de) * 2015-09-30 2023-01-25 Icosagen Cell Factory OÜ Methode zur entwicklung monoklonaler antikörper
MY207225A (en) 2015-10-27 2025-02-06 UCB Biopharma SRL Methods of treatment using anti-il-17a/f antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method
EP3241845A1 (de) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanisierte anti-il-1r3-antikörper
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
EP3471754A1 (de) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1-antikörper
SG10201913858WA (en) 2016-08-26 2020-03-30 Agency Science Tech & Res Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
MA47106A (fr) 2016-12-21 2019-10-30 Amgen Inc Formulations d'anticorps anti-tnf alpha
EP3401332A1 (de) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antikörper zur verwendung bei entzündungskrankheiten
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
AU2019289176A1 (en) 2018-06-18 2020-12-24 Oxford University Innovation Limited Gremlin-1 antagonist for the prevention and treatment of cancer
SG11202103801UA (en) 2018-10-16 2021-05-28 UCB Biopharma SRL Method for the treatment of myasthenia gravis
GB201817309D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201817311D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
AU2019370339B2 (en) 2018-11-01 2024-07-11 Shandong New Time Pharmaceutical Co., Ltd. Bispecific antibody and use thereof
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
EP4103609A1 (de) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispezifische antikörper gegen cd9 und cd7
WO2021160266A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies binding hvem and cd9
US20230151108A1 (en) 2020-02-13 2023-05-18 UCB Biopharma SRL Bispecific antibodies against cd9 and cd137
WO2021160268A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies against cd9
US20230125234A1 (en) 2020-02-13 2023-04-27 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
EP4229085A1 (de) 2020-10-13 2023-08-23 Almirall S.A. Bispezifische moleküle und behandlungsverfahren damit
MX2023004436A (es) 2020-10-15 2023-05-08 UCB Biopharma SRL Moleculas de union que multimerizan cd45.
US20230406924A1 (en) 2020-11-02 2023-12-21 UCB Biopharma SRL Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
AU2021395729A1 (en) 2020-12-07 2023-07-13 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
AR124250A1 (es) 2020-12-07 2023-03-01 UCB Biopharma SRL Anticuerpos
EP4294834A2 (de) 2021-02-19 2023-12-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Einzeldomänenantikörper zur neutralisierung von sars-cov-2
JP2024509971A (ja) 2021-03-11 2024-03-05 アイジェニックス， インコーポレイテッド アレルギー応答を予測するための方法およびシステム
EP4067381A1 (de) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Neue tnfr2-bindende moleküle
AU2022261268A1 (en) 2021-04-22 2023-11-16 Guangdong Fapon Biopharma Inc. Bispecific multifunctional fusion polypeptide
BR112023022844A2 (pt) 2021-05-03 2024-01-23 UCB Biopharma SRL Anticorpos
WO2023285878A1 (en) 2021-07-13 2023-01-19 Aviation-Ophthalmology Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
EP4580753A1 (de) 2022-08-31 2025-07-09 Washington University Alphavirus-antigen-bindende antikörper und verwendungen davon
KR20250060305A (ko) 2022-09-21 2025-05-07 사노피 바이오테크놀로지 인간화 항-il-1r3 항체 및 사용 방법
EP4605077A1 (de) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Gegen den melanocortin-4-rezeptor gerichtete aminosäuresequenzen und polypeptide damit zur behandlung von mc4r-bedingten erkrankungen und störungen
JP2025539866A (ja) 2022-11-28 2025-12-09 ユーシービー バイオファルマ エスアールエル 線維筋痛症の処置
WO2025101487A1 (en) * 2023-11-06 2025-05-15 Bruker Cellular Analysis, Inc. Affinity assay for microfluidic devices
GB202318820D0 (en) 2023-12-08 2024-01-24 UCB Biopharma SRL Antibodies
TW202540204A (zh) 2024-01-26 2025-10-16 西班牙商阿爾米雷爾有限公司 雙特異性分子及使用其的治療方法
WO2025238135A2 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Antibody with binding specificity for il-11
WO2025238133A1 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Multispecific antibody with binding specificity for il-11 and il-17

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
DK0488470T3 (da) * 1990-11-26 1997-12-22 Akzo Nobel Nv Fremgangsmåde til fremstilling af antistoffer
GB9718911D0 (en) * 1997-09-05 1997-11-12 Orion Yhtymae Oy Monoclonal antibodies
US20050147609A1 (en) * 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
WO2000044777A1 (en) * 1999-01-29 2000-08-03 Imclone Systems Incorporated Antibodies specific to kdr and uses thereof
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products

Also Published As

Publication number Publication date
EP1633787B1 (de) 2010-03-03
AU2004242823A1 (en) 2004-12-09
JP2007535485A (ja) 2007-12-06
DE602004025805D1 (de) 2010-04-15
CA2526546A1 (en) 2004-12-09
WO2004106377A1 (en) 2004-12-09
US20070009959A1 (en) 2007-01-11
JP4624357B2 (ja) 2011-02-02
US7790414B2 (en) 2010-09-07
EP1633787A1 (de) 2006-03-15
GB0312481D0 (en) 2003-07-09
ES2341544T3 (es) 2010-06-22

Similar Documents

Publication Publication Date Title
ATE459652T1 (de) Verfahren zur herstellung von antikörpern
ATE554390T1 (de) Verfahren zur gewinnung von antikörpern
ATE292282T1 (de) Verfahren zur zellseparation unter verwendung von immunorosetten
DE60219321D1 (de) Einzelketten vhh antikörper aus kamelen, verfahren zur deren herstellung in einem saugetier und deren verwendungen
ATE468390T1 (de) System und verfahren zur produktion von antikörpern in der pflanzenzellkultur
EP1427445A4 (de) Verfahren zur reifung von plasmacytoiden dendritischen zellen unter verwendung von die immunantwort modifizierenden molekülen
EP2534257A4 (de) Verfahren zur identifikation und isolierung von zellen zur expression von polypeptiden
ATE556091T2 (de) Monoklonale antikörperproduktion durch ebv transformation von b-zellen
EA200800996A1 (ru) Способ получения т-клеточной популяции
WO2006127809A3 (en) Methods for expansion and analysis of cultured hematopoietic stem cells
DE60314898D1 (de) Zusammensetzungen und verfahren zur trennung von zellen
IL165390A0 (en) Methods for identifying and extracting endotoxin
ATE479743T1 (de) Verfahren zur herstellung von zellkulturen aus biologischen präparaten für chemotherapeutische und andere assays
ATE279441T1 (de) Verfahren zur herstellung von genetisch veränderten lymphozyten vorläuferzellen von wirbeltieren und deren gebrauch zur produktion von heterologen bindeproteinen
TW200741000A (en) Method of producing lymphocytes
DE60319599D1 (de) Verfahren zur differenzierung einer mesenchym-stammzelle zu einer nervenzelle sowie die nervenzelle eine neurodegenerative krankheit
ATE469917T2 (de) Verfahren zur gewinnung von antikörpern
EP1645183A4 (de) Verfahren zur herstellung von immunkompetenten zellen menschlichen ursprungs
WO2001079541A3 (en) Improvements in and relating to analysis of dna samples
ATE505535T1 (de) Verfahren zur herstellung stabiler b-lymphozyten
IL164625A (en) Method for producing a plurality of monoclonal antibodies and method for identifying a plurality of monoclonal antibodies
WO2009102697A3 (en) Methods of obtaining antigen-specific t cell populations
ATE307193T1 (de) Verfahren zur abtrennung von lebensfähigen säuger-oder insekten-zellen aus zellsuspensionen
ATE345397T1 (de) Verfahren zur isolierung von bakterien aus biologischen proben
ATE346865T1 (de) Zusammensetzungen und verfahren zur herstellung monoklonaler antikörper, repräsentativ für einen spezifischen zelltyp

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties